Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ontruzant Neoadjuvant in HER2+ Early Breast Cancer
NCT05036005Phase 4Unknown
- Sponsor
- Institut Frauengesundheit
- Start
- Jul 2021
- Primary completion
- Apr 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of trastuzumab in HER2-positive breast cancer, sponsored by Institut Frauengesundheit. Status: unknown.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05036005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05036005.